Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Irinotecan‐based regimens showed no clear difference in severe adverse effects compared with irinotecan (moderate certainty).
Irinotecan + oxaliplatin probably leads to lower overall survival compared with irinotecan (moderate certainty).
Irinotecan + oxaliplatin probably leads to lower progression‐free survival compared with irinotecan (moderate certainty).
Irinotecan + oxaliplatin probably leads to higher overall tumour response compared with irinotecan (moderate certainty).
Irinotecan + oxaliplatin probably leads to higher severe adverse effects compared with irinotecan (moderate certainty).
Chemotherapy probably leads to lower overall survival compared with best supportive care (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Modern chemotherapy regimens leads to lower progression‐free survival compared with 5‐flourouracil (high certainty).
Chemotherapy probably leads to higher severe adverse effects compared with best supportive care (moderate certainty).
FOLFIRI + targeted therapy leads to lower overall survival compared with FOLFIRI (high certainty).
FOLFIRI + targeted therapy leads to lower progression‐free survival compared with FOLFIRI (high certainty).
FOLFIRI + targeted therapy probably leads to higher overall tumour response compared with FOLFIRI (moderate certainty).
FOLFIRI + targeted therapy probably leads to higher severe adverse effects compared with FOLFIRI (moderate certainty).
It is very uncertain whether FOLFOX + targeted therapy changes overall survival compared with FOLFOX (very low certainty).
FOLFOX + targeted therapy may leads to lower progression‐free survival compared with FOLFOX (low certainty).
FOLFOX + targeted therapy probably leads to higher overall tumour response compared with FOLFOX (moderate certainty).
FOLFOX + targeted therapy leads to higher severe adverse effects compared with FOLFOX (high certainty).
Irinotecan + targeted therapy showed no clear difference in overall survival compared with irinotecan (low certainty).
Modern chemotherapy regimens leads to higher overall tumour response compared with 5‐flourouracil (high certainty).